ÂÜÀòÂÒÂ×

David Dangoor, PhD, MBA has extensive work experience in business development and consulting roles in the pharmaceutical industry. David is currently serving as the Director of Business Development at Clexio Biosciences, a clinical-stage pharmaceutical company focused on developing innovative treatments for CNS indications. Prior to this, they held the position of Business Development Lead at Clexio Biosciences and also served as a Business Development, Analyst, and Technology Scout at the company. Before joining Clexio Biosciences, David worked at Alcobra, where they were involved in business development, analysis, and technology scouting for the development of new medications for cognitive disorders. David also worked as a Business Consultant and Programmes Director at OSM DAN LTD, where they managed European research and development projects. David's academic background includes postdoctoral research positions at UCSD and HHMI, where they focused on molecular medicine and interferon signaling.

David Dangoor holds a Ph.D. in Clinical Biochemistry & Organic Chemistry from the Weizmann Institute of Science, which they completed from 2001 to 2006. David also obtained a M.Sc. degree in Drug Delivery and Nanoparticles from The Hebrew University of Jerusalem during the academic year 2000-2001. Prior to that, they completed their B.Pharm in Pharmaceuticals from The Hebrew University of Jerusalem from 1994 to 1999. Additionally, they pursued a BioMBA from The College of Management Academic Studies, which they completed in 2017.